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Introduction: We present the case of a 40-year-old man with severe rheumatoid arthritis being treated with
high-dose anti-tumor necrosis factor α therapy (adalimumab), who developed simultaneous lymphoma and breast
cancer with lymph node metastases. We describe strategies for investigations and management of this
presentation.
Case presentation: A 40-year-old Caucasian man with severe rheumatoid arthritis being treated with high-dose
adalimumab presented to our facility with a swollen leg and palpable left groin and left axillary lumps and a left
nipple lesion. Left lower limb ultrasound, computed tomography and positron emission tomography scans showed
extensive lymphadenopathy. Core biopsies of the left groin, axilla and nipple lesion showed this to be concurrent
diffuse B-cell lymphoma and locally metastatic invasive ductal carcinoma of the breast. He underwent a left
mastectomy with axillary clearance, and adjuvant fluorouracil, epirubicin and cyclophosphamide chemotherapy with
rituximab, and the adalimumab was stopped.
Conclusions: The findings from our patient’s case should increase awareness that patients with severe rheumatoid
arthritis, especially if they are on high-dose biological treatments, have the potential to develop lymphoma, which
in turn increases the risk of developing other primary tumors, so that in rare cases a patient may have concurrent
tumors. Assessment and management of these patients is challenging and should include computed tomography
scans of the of neck, thorax, abdomen and pelvis, including a fludeoxyglucose positron emission tomography/
computed tomography scan, bone marrow testing and appropriate core biopsies and discussion at multidisciplinary
team meetings about treatment of the separate tumors in the presence of hematologists, oncologists, surgeons
and rheumatologists.
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We present the case of a Caucasian man with rheumatoid
arthritis (RA) who was being treated with adalimumab
(HumiraW, Abbott Laboratories, Global Health Care and
Medical Research, 100 Abbott Park Road, Abbott Park,
Illinois, USA), an anti-tumor necrosis factor α (TNFα)
biological agent, who developed synchronous B-cell
lymphoma and locally metastatic breast cancer. RA is a
chronic inflammatory condition resulting in destructive
arthropathy of joints. The pathophysiology involves an
autoimmune activation of T helper lymphocytes, antigen-
presenting cells and production of cytokines such as
TNFα acting against joint synovium. The advent of bio-
logical therapies, which inhibit inflammatory pathways,
have had success in the treatment of RA.
The immunosuppressive effects of biological agents such
as adalimumab have the potential concern of increasing
the risk of lymphoma, although the evidence for this in RA
is controversial, as severe cases of RA are usually on
adalimumab and increased disease severity itself is an
increased risk factor of developing lymphoma.
Lymphoma is a hematological cancer affecting the
lymphatic system. The lymphocytes are cancerous and
functionally abnormal resulting in an immunosuppressed
state. This is associated with an increased risk of develo-
ping other types of primary malignancies ranging from
colorectal cancer to breast cancer [1].
This case report highlights that when patients with RA
who have been on biological agents present with unusual
symptoms it is necessary to consider lymphoma and
a synchronous second primary neoplasm, and suggests
diagnostic and therapeutic strategies for addressing this
situation.
Case presentation
A 40-year-old Caucasian man with a background of se-
vere seropositive RA affecting his shoulders, wrists and
left hip was worked up for an elective total hip replace-
ment (THR). He had a medical history of RA, diagnosed
14 years previously, for which he had been taking adali-
mumab (two weekly injections) for seven years, metho-
trexate 20mg weekly, salazopyrin 1g twice a day and
prednisolone 1mg once a day. He had no other medical
conditions and no family history of cancer. He was a
former heavy smoker (quit four years ago, 40 pack-years)
and drank 24 units of alcohol per week. On admission
for his left THR, pre-operatively it was discovered that
his entire left leg had been swollen for three weeks. He
reported no other symptoms, including systemic symp-
toms of weight loss or night sweats. The operation was
cancelled. An ultrasound scan of the left lower limb
showed no deep vein thrombosis, but multiple abnormal
looking lymph nodes in the groin were seen. He went on
to have a computed tomography (CT) scan of his thorax,abdomen and pelvis. This demonstrated extensive lymph-
adenopathy affecting axillae, inguinal regions, mediastinum
and retroperitoneum. The lymph nodes were particularly
bulky in the left axilla, retroperitoneum and left inguinal
regions. The CT scan also showed a left nipple mass.
Our patient was referred to a hematologist and a
breast surgeon for specialist assessment. The history was
as noted above. On examination, added to the swollen
left leg, bilateral axillary lymph nodes were palpable
which were more bulky on the left, a 5 × 3cm hard left
groin lymph node was palpable and a nodular grape-like
pink lesion 2cm in diameter was seen over the left nipple.
There was no hepatosplenomegaly palpable. Our patient’s
adalimumab injections were stopped permanently after
consultation with a rheumatologist. Our patient under-
went core biopsies of the left nipple lesion, left axilla, left
groin and bone marrow biopsy. Histology and immunos-
taining studies showed the left nipple lesion was an
intermediate grade invasive ductal carcinoma of the breast
with no lympho-vascular invasion. The groin biopsy
showed a relatively homogeneous lymphoid cell popula-
tion with mainly small lymphocytes demonstrating atypia
suspicious for lymphoma. Test results revealed the cells
were CD20+, CD5 negative, B-cell lymphoma (bcl)-6 posi-
tive and bcl-2 positive, in keeping with a B-cell lymphoma.
The bone marrow biopsy was essentially normocellular
except for a single paratrabecular cluster of lymphoid cells
containing CD20+ B cells and CD3+ T cells suspicious for
a follicular lymphoma. Fluorescence in situ hybridization
(FISH) carried out on the groin lymph node core biopsy
sample was inconclusive, with inconsistent translocations
of bcl-2 and many cells showing an amplification of part
of chromosome 18, the overall significance of which was
uncertain, but could not confirm or exclude that this was
a follicular B-cell lymphoma. The core biopsy of the
left axilla sampled three separate lymph nodes which
contained metastatic adenocarcinoma of the breast.
Our patient went on to have a fludeoxyglucose (FDG)
positron emission tomography (PET)-CT scan from the
base of the skull to the mid-thighs. This showed a focal
intense uptake in the left breast in the region of the known
breast cancer, and increased uptake patterns consistent
with extensive nodal disease above and below the
hemidaiphragm, particularly bulky in the retroperitoneum
and left inguinal region, consistent with the original CT
scan. Increased uptake in the axilla and supraclavicular
regions was seen, but it was not possible from the PET-
CT scan to assess whether they represented nodes from
lymphoma or metastatic breast cancer. All these results
were discussed at the hemoncology and breast multidis-
ciplinary team meeting and a decision was made to
proceed with a left mastectomy and axillary clearance.
The histology of this showed a 22mm low-grade invasive
ductal carcinoma with prominent lymphatic invasion and
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and no evidence of Paget’s disease of the nipple. The
tumor tested positive for estrogen receptor (8/8) and posi-
tive for progesterone receptor (6/8), but negative for
human epidermal growth factor receptor 2 (Her-2). The
left axillary contents contained 20 lymph nodes, five out
of 20 nodes contained metastatic breast adenocarcinoma,
all the others contained lymphoma. There was one lymph
node, half of which was involved with metastatic breast
cancer, and the other half with lymphoma (Figure 1). Our
patient went on to have adjuvant chemotherapy to cover
the breast cancer and lymphoma consisting of a regimen
of fluorouracil, epirubicin and cyclophosphamide (FEC)
chemotherapy with rituximab and thromboprophylaxis
with enoxaparin 40mg subcutaneously once a day.Discussion
In the current report we describe the case of a 40-year-old
Caucasian man with severe RA diagnosed 14 years previ-
ously who had been treated with high-dose adalimumab
for seven years, who presented with a swollen leg and
palpable left groin and left axillary lumps and a left nipple
lesion. Left lower limb ultrasound, CT and PET scans
showed extensive lymphadenopathy. Core biopsies of the
left groin, axilla and nipple lesion showed this to be con-
current diffuse B-cell lymphoma and locally metastatic
invasive ductal carcinoma of the breast. He underwent a
left mastectomy with axillary clearance, adjuvant FEC
chemotherapy with rituximab and the adalimumab was
stopped. When abnormal lymph nodes are demonstrated
clinically with or without ultrasound scanning in a patient
with RA on biological treatment such as adalimumab, it is
reasonable to do full staging with a CT scan of the neck,
thorax, abdomen and pelvis, with directed core biopsies toFigure 1 (A) axillary lymph node replaced by lymphoma. (B)
Second lymph node from same axillary lymph node specimen
showing second lymph node replaced by metastatic invasive ductal
carcinoma of the breast.assess the extent and nature of the lymphadenopathy and
to guide management.
In our patient’s case it is difficult to ascertain whether
severe long-term RA alone or adalimumab treatment of
RA was the risk factor that contributed to development of
lymphoma. It is recognised that RA increases the risk of
developing lymphoma, especially for severe and long-
standing disease, although the precise mechanism for this
is not understood. Adalimumab is an anti-TNFα antibody,
which is a biological therapy for RA. It is difficult to assess
the contribution of anti-TNFα therapy to developing
lymphoma, as patients with severe RA are the same
patients on anti-TNFα therapy. Evidence from observa-
tional cohort studies using more than 15,000 patients
found no increased risk of lymphoma or any solid tumors
in patients with RA receiving anti-TNFα treatment,
although RA was more severe in the group receiving the
biological treatment. In another cohort study with over
1500 patients with RA after adjusting for age, sex and
disease severity there was a small increased risk (hazard
ratio 5.0) of developing lymphoma in the RA group treated
with a TNFα inhibitor (five lymphomas in treatment RA
group versus two lymphomas in the reference RA group)
[2]. This finding has to be interpreted with caution because
of the small number of lymphomas (a total of seven) and
short follow-up period of four years [3]. In response to
reports of lymphomas through post-marketing surveil-
lance, the Food and Drug Administration (FDA) sum-
marised data from clinical trials for all TNFα inhibitors.
They found that lymphomas were rare occurrences in both
treatment and placebo groups with a trend towards a small
increase in the treatment group, which was not statistically
significant. Bongartz et al. conducted a meta-analysis of
nine randomized controlled trials (RCTs) of anti-TNFα
treatment of RA [4]. The odds ratio (OR) for overall malig-
nancy was 2.4 (95% confidence interval [CI] 1.2 to 4.8) with
skin cancer being the most common malignancy and
lymphoma the second most common with 10 cases in the
treatment group and zero cases in the placebo group. The
risk of malignancy was dose related with high-dose TNFα
inhibitor therapy having an increased OR of 4.3 (95% CI
1.6 to 11.8). In summary, neither has a causal relationship
between anti-TNFα therapy for RA and lymphoma been
established or ruled out. Severe longstanding RA does
increase the risk of developing lymphoma. In our patient’s
case it is impossible to say what the causative factor was,
but it is likely to have been either RA or adalimumab [5].
In our patient’s case he had also been taking metho-
trexate. This is an immunosuppressant agent. The question
of whether such agents increase the risk of malignancy in
RA has been previously addressed. A cohort study of 789
randomly selected patients with RA between 1999 and
2005 found that methotrexate did not increase the risk of
cancer although other immunosuppressant agents did
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found that there was increased risk of malignant melanoma
with methotrexate with a standardized incidence ratio of
3.0 (95% CI 1.2 to 6.2) [7], although another group found
no increased risk of skin cancer with methotrexate in a
study of 15,789 patients with RA [8]. A review of this sub-
ject found that the use of methotrexate in patients with RA
did not increase the risk of cancers, although azathioprine
increased the risk of developing lymphomas and cyclophos-
phamide increased the risk of cancers, particularly bladder
cancer [5]. The current evidence indicates that there is no
increased risk of developing non-cutaneous malignancies
with the use of methotrexate in RA.
Lymphoma increases the risk of developing other pri-
mary cancers, as the abnormal lymphocytes result in a
functionally immunosuppressed state. Immunosuppression
increases the risk of developing other primary malignan-
cies, as a functioning immune system can detect abnormal
epitopes on the surface of some cancer cells, which acti-
vates an immune response to destroy those cells. In our
patient’s case it is likely that lymphoma contributed to the
development of breast cancer, as this was a man with no
family history of cancer. Once lymphoma has been identi-
fied on initial imaging and histologically, it is reasonable to
do a FDG PET-CT scan not only to assess the extent of
disease but also to identify possible locations of other pri-
mary tumors. Once diagnosis of lymphoma is confirmed, a
PET-CT scan to assess the extent of lymphoma and iden-
tify any other occult primary tumor is already considered
good practice [1]. This proved to be so in our patient’s case,
where the primary breast cancer was identified.
This case report should increase awareness that patients
with severe RA, especially if they are on high-dose bio-
logical treatments, have the potential for developing lymph-
oma, which in turn increases the risk of developing other
primary tumors so that in rare cases a patient may have
concurrent tumors. Assessment and management of these
patients is challenging and should include a CT scan of the
neck, thorax, abdomen and pelvis, including an FDG
PET-CT scan, bone marrow test and appropriate core biop-
sies and discussion at multidisciplinary team (MDT) mee-
tings about treatment of the separate tumors in the
presence of hematologists, oncologists, surgeons and rheu-
matologists. Our patient’s case was discussed at five MDT
meetings during our patient’s treatment process.Conclusions
Patients with severe RA on anti-TNFα treatment may in
rare cases develop concurrent lymphoma and another pri-
mary tumor. This should be considered in all such patients
undergoing investigation and management for either a
lymphoma or another primary tumor so as not to miss the
concurrent tumor and an opportunity to treat both. Thesedecisions should be made in the setting of MDT meetings
incorporating all the involved specialists.
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